PET scanner for Biomedical Engineers: Principles, Components, Clinical Applications, and Emerging Innovations

The PET scanner (Positron Emission Tomography) is a cornerstone of modern nuclear medicine, providing unparalleled functional and metabolic imaging of the human body. Unlike anatomical modalities such as CT or MRI, PET detects the distribution of radiolabeled tracers by measuring 511 keV annihilation photons produced when positrons emitted from the tracer collide with electrons in tissue. This capability to image physiology at the molecular level has made PET an indispensable tool in oncology, neurology, and cardiology, and has driven decades of engineering innovation in detector physics, coincidence electronics, and image reconstruction.

1. What is a PET Scanner?

Definition and Brief History

A PET scanner is a medical imaging device that detects gamma radiation emitted indirectly by a positron-emitting radioisotope (radiotracer) introduced into the body. It reconstructs three-dimensional images of tracer concentration, reflecting underlying physiological and biochemical processes such as glucose metabolism, receptor binding, or blood flow. As part of the broader field of radiological devices, PET occupies a unique position because it measures function rather than anatomy.

The history of PET begins in the early 1950s when Gordon Brownell and Charles Burnham at Massachusetts General Hospital first demonstrated annihilation-coincidence detection using NaI detectors for brain tumor localization. In 1961, James Robertson at Brookhaven National Laboratory constructed the first single-plane ring scanner, and together with Zang-Hee Cho proposed the cylindrical multi-ring architecture. The landmark advance came in 1974 when Michael Ter-Pogossian, Marcus Raichle, and colleagues at the Mallinckrodt Institute developed the first multislice cylindrical PET scanner (PETT III), enabling volumetric imaging. Commercial PET systems such as the Siemens ECAT series emerged in the late 1970s, and the integration of PET with CT in the mid-1990s by David Townsend and Ron Nutt created the hybrid PET/CT platform that dominates clinical practice today.

The Physics of Positron Emission

PET imaging is grounded in the physics of beta-plus (β+) decay. A proton-rich radionuclide such as fluorine-18 (¹⁸F, half-life 110 minutes) undergoes β+ decay, emitting a positron from the nucleus. The emitted positron travels only a short distance in tissue — typically less than 1 mm for ¹⁸F — before losing kinetic energy and undergoing annihilation with a nearby electron. This matter-antimatter annihilation event produces two 511 keV gamma photons emitted simultaneously at approximately 180° to each other, conserving both energy and momentum.

These back-to-back photon pairs are the fundamental signal detected by PET scanners. The energy of 511 keV corresponds exactly to the rest mass energy of an electron (or positron), given by Einstein’s relation E = mc². The near-simultaneous detection of both photons by opposing detectors — within a coincidence timing window of 6–12 nanoseconds — defines a line of response (LOR) passing through the annihilation point, enabling tomographic reconstruction without a physical collimator. This electronic collimation gives PET a significant sensitivity advantage over single-photon techniques such as SPECT.

PET in the Context of Nuclear Medicine

Nuclear medicine exploits the biodistribution of radiolabeled molecules to interrogate physiological processes non-invasively. PET radiotracers are designed by labeling biologically active molecules with positron-emitting isotopes. The most widely used tracer, ¹⁸F-fluorodeoxyglucose (FDG), is a glucose analog that accumulates in cells with high metabolic activity — particularly malignant tumors, inflammatory tissue, and metabolically active brain regions. Other important tracers include ¹¹C-Pittsburgh compound B (PiB) and ¹⁸F-florbetapir for amyloid imaging in Alzheimer’s disease, ⁸²Rb-chloride and ¹³N-ammonia for myocardial perfusion, and ⁶⁸Ga-PSMA-11 for prostate cancer staging.

The diversity of available radiotracers means that PET is not a single imaging modality but a flexible platform capable of interrogating dozens of biological targets. This versatility has driven sustained investment in PET instrumentation, radiopharmacy infrastructure, and computational reconstruction — making it one of the most technically complex and clinically impactful devices in modern biomedicine.

2. Why is a PET Scanner Used?

Oncology: Staging, Response Assessment, and Surveillance

FDG-PET/CT is the standard of care for staging and restaging of many cancers, including lung cancer, lymphoma, colorectal cancer, melanoma, and head-and-neck cancers. Tumors typically demonstrate elevated glucose metabolism (the Warburg effect), resulting in FDG avidity that distinguishes malignant from benign tissue with high sensitivity. A single whole-body FDG-PET/CT scan can simultaneously evaluate the primary tumor, regional lymph nodes, and distant metastases — a staging efficiency unmatched by anatomical imaging alone. As explored in detail in our article on cancer diagnosis and treatment, biomedical engineering advances in PET have directly improved oncologic outcomes.

Beyond initial staging, PET is used to assess treatment response mid-therapy — a capability that allows oncologists to modify chemotherapy or radiation regimens based on metabolic response before anatomical changes become visible. The Deauville criteria for lymphoma and PERCIST criteria for solid tumors provide standardized frameworks for interpreting PET response. Surveillance PET scans detect early recurrence, often months before clinical symptoms or CT findings. For high-risk patients, the impact of PET-guided management on survival is well-documented in randomized controlled trials.

Neurology: Brain Function, Neurodegeneration, and Epilepsy

In neurology, PET provides irreplaceable information about brain function and disease mechanisms. FDG-PET reveals patterns of regional hypometabolism characteristic of neurodegenerative diseases: the temporoparietal pattern in Alzheimer’s disease, asymmetric posterior cortical involvement in Lewy body dementia, and frontal hypometabolism in frontotemporal dementia. Amyloid PET tracers (¹⁸F-florbetapir, ¹⁸F-florbetaben, ¹⁸F-flutemetamol) allow direct visualization of amyloid-beta plaques in the living brain, enabling definitive diagnosis of Alzheimer’s pathology years before clinical dementia onset. Tau PET tracers further enable staging of neurofibrillary tangle spread according to Braak staging.

Epilepsy surgery planning relies on ictal and interictal FDG-PET to localize seizure foci: the epileptogenic zone is hypermetabolic during seizures but hypometabolic interictally. In patients with refractory epilepsy who are candidates for resective surgery, PET-MRI co-registration has substantially improved surgical planning accuracy. Additionally, dopaminergic PET tracers (¹⁸F-FDOPA, ⁶⁸Ga-DOTATOC) are used in Parkinson’s disease and neuroendocrine tumor imaging, reflecting the breadth of neurological and oncological applications.

Cardiology: Myocardial Viability and Perfusion Imaging

Cardiac PET imaging addresses two primary clinical questions: myocardial perfusion (is blood flow adequate?) and myocardial viability (is hibernating myocardium salvageable by revascularization?). ⁸²Rb-chloride (half-life 76 seconds, generator-produced) and ¹³N-ammonia (half-life 10 minutes, cyclotron-produced) are the main perfusion tracers. Absolute quantification of myocardial blood flow in mL/min/g — a unique capability of PET compared to SPECT — enables detection of balanced three-vessel disease that may be missed by relative perfusion imaging. FDG-PET for viability identifies metabolically active but dysfunctional myocardium (hibernating myocardium) that will recover function after revascularization, directly guiding surgical decisions in ischemic cardiomyopathy.

Cardiac PET is also used in inflammatory cardiac disease, including cardiac sarcoidosis and infective endocarditis on cardiac implants, where FDG accumulation in otherwise quiescent myocardium reveals active inflammation. For biomedical engineers working with cardiovascular devices, understanding the role of PET in evaluating device-related complications is increasingly important as implantable cardiac devices proliferate.

3. How Does a PET Scanner Work?

Radiotracer Administration and Biodistribution

A PET study begins with intravenous administration of the radiotracer. For FDG-PET, the patient fasts for at least 4–6 hours to minimize background glucose competition, and blood glucose is confirmed below 150–200 mg/dL. The injected activity is typically 3–5 MBq/kg for adults (approximately 200–400 MBq for a standard adult). After injection, the patient rests in a quiet, low-light environment for approximately 45–60 minutes to allow FDG to distribute and be taken up by metabolically active tissues. During this uptake period, the tracer equilibrates and phosphorylated FDG-6-phosphate becomes metabolically trapped in cells proportional to their glucose utilization rate.

For cardiac perfusion studies with ⁸²Rb, the very short half-life (76 seconds) means imaging begins almost immediately after injection using a dedicated infusion system connected to a strontium-82/rubidium-82 generator, allowing stress-rest protocols to be completed within 30–45 minutes. The diversity of tracer kinetics — from the rapid washout of perfusion tracers to the prolonged retention of receptor-binding agents — requires flexible scanner acquisition protocols and sophisticated kinetic modeling software.

Coincidence Detection and Lines of Response

The PET scanner’s detector ring surrounds the patient and continuously monitors for pairs of 511 keV photons arriving within the coincidence timing window (typically 4–10 ns in modern systems). When two detectors register photon interactions within this window, a coincidence event is recorded, and a line of response (LOR) is drawn between the two detector elements. The collection of millions of LORs from all detector pairs forms the raw data — typically stored as a sinogram or in list-mode format — from which the three-dimensional tracer distribution is reconstructed.

Three types of coincidence events occur: true coincidences (both photons from the same annihilation, carrying valid spatial information), scattered coincidences (one or both photons have been deflected by Compton scattering, carrying erroneous spatial information), and random coincidences (two photons from different annihilation events are falsely registered as a pair). Scatter and random events degrade image contrast and quantitative accuracy; they are corrected using energy windowing, scatter correction algorithms (Monte Carlo simulation or model-based), and delayed coincidence windows for randoms estimation. In modern 3D PET acquisitions — which remove the tungsten septa between detector rings used in 2D mode — sensitivity increases dramatically but scatter fraction also rises to 30–50%, making accurate scatter correction essential.

Image Reconstruction, Attenuation Correction, and TOF-PET

Raw PET data undergoes several corrections before image reconstruction. Attenuation correction is the most critical: 511 keV photons are attenuated as they traverse body tissues, and without correction, deeper structures appear artifactually cold. In PET/CT, the CT scan provides a spatially registered attenuation map that is scaled from X-ray energies to 511 keV. In PET/MRI, MR-based attenuation correction using Dixon sequences or atlas-based methods is used, though bone representation remains challenging. Normalization corrections account for detector efficiency variations, and dead-time corrections address count rate losses at high activity concentrations.

Reconstructed images are computed using either analytical methods (filtered backprojection, FBP) or iterative algorithms. The ordered-subsets expectation maximization (OSEM) algorithm, the clinical standard, divides projection data into subsets and iteratively updates the image estimate to maximize the likelihood of the measured data. Time-of-flight (TOF) PET exploits the sub-nanosecond difference in arrival times of the two annihilation photons to constrain the annihilation point along the LOR to a short segment (~10 cm for 200 ps timing resolution), dramatically improving signal-to-noise ratio. TOF reconstruction is particularly beneficial for large patients and low-count studies, improving lesion detectability without additional radiation dose.

4. Main Components of a PET Scanner

Detector Rings and Scintillator Crystals

The detector ring is the defining structural feature of a PET scanner. It consists of thousands of small scintillator crystals arranged in a cylindrical array, typically 60–90 cm in diameter, with an axial field of view (FOV) of 15–30 cm in conventional systems. The scintillator converts the 511 keV photon into a burst of visible light photons that is then detected by a photodetector. The choice of scintillator material profoundly influences scanner performance: key parameters are light yield (photons per MeV), decay time (determines timing resolution), density and effective atomic number (determines sensitivity), and energy resolution (determines scatter rejection ability).

The evolution of scintillator materials tracks the history of PET performance improvements. Early scanners used sodium iodide (NaI:Tl), widely available but with slow decay time (~250 ns) limiting count rate performance. Bismuth germanate (BGO), introduced in the 1980s, offered higher density (7.13 g/cm³) and stopping power, improving sensitivity, but had even slower decay (~300 ns) and low light yield. Lutetium oxyorthosilicate (LSO) and lutetium-yttrium oxyorthosilicate (LYSO), developed in the 1990s–2000s, combined high density, excellent light yield, and fast decay time (~40 ns), enabling time-of-flight PET and higher count rates. LYSO remains the dominant scintillator in modern clinical and research PET systems.

Photodetectors: PMTs vs. Silicon Photomultipliers

Photodetectors convert the scintillation light into an electrical signal. Traditional PET systems used photomultiplier tubes (PMTs): vacuum tube devices that amplify single photons through a cascade of dynodes to produce a measurable current pulse. PMTs offer excellent single-photon sensitivity and low noise, but are bulky, fragile, require high voltage (~1000 V), and are fundamentally incompatible with strong magnetic fields — making them unsuitable for PET/MRI systems. In block detector designs, a small number of PMTs (typically 4) are coupled to a larger array of crystals using a light guide, with crystal identification achieved by comparing relative signal amplitudes across the PMT channels.

Silicon photomultipliers (SiPMs) — also called multi-pixel photon counters (MPPCs) — are arrays of single-photon avalanche diodes operated in Geiger mode on a common silicon substrate. SiPMs offer exceptional timing resolution (enabling the <210 ps coincidence timing resolution of the Siemens Biograph Vision), compact form factor, low operating voltage (~25–35 V), insensitivity to magnetic fields (enabling PET/MRI), and individual crystal readout capability that eliminates the crystal identification ambiguity of block detectors. The transition from PMT-based to SiPM-based “digital PET” represents the most significant detector technology shift since the introduction of LSO, with every major manufacturer now offering SiPM-based systems.

Coincidence Processing Electronics and Data Acquisition

The coincidence processing unit is the electronic heart of the PET scanner. It receives timestamped detector hits from all channels and identifies pairs of interactions within the coincidence timing window. Modern systems use application-specific integrated circuits (ASICs) that perform constant fraction discrimination for precise timing, energy discrimination to reject non-511 keV photons, and high-speed digital coincidence sorting. Data acquisition systems must process event rates of tens of millions of singles per second at clinical activity levels, requiring sophisticated dead-time management and pipelining.

List-mode acquisition records each coincidence event with its detector pair identifiers, energy values, and timestamp, providing maximal flexibility for offline reconstruction with arbitrary time framing and motion correction. Alternatively, sinogram-mode acquisition histograms events into projection bins in real time, reducing data storage requirements. The reconstruction computer applies all corrections and iterative algorithms, typically requiring graphics processing unit (GPU) acceleration to achieve clinically acceptable reconstruction times of minutes rather than hours for high-resolution TOF-OSEM reconstruction with point spread function (PSF) modeling.

Gantry, Patient Table, and Radiopharmacy Infrastructure

The PET gantry houses the detector rings and associated electronics within a shielded enclosure. The bore diameter is typically 70–80 cm to accommodate patients of varying habitus. Radiofrequency shielding is incorporated in PET/MRI systems to prevent interference between the MR transmit coils and the PET electronics. The motorized patient table advances the patient through the bore in discrete steps (or continuously in continuous-bed-motion acquisition), with each bed position providing coverage of one axial FOV. For whole-body oncology studies, 5–7 overlapping bed positions are acquired over approximately 15–20 minutes.

Radiopharmacy infrastructure is an often-overlooked but essential component of a PET program. Short-lived positron-emitting isotopes must be produced close to the point of use: ¹⁸F (half-life 110 min) requires a medical cyclotron within approximately 2–3 hours of the imaging site, or centralized commercial production with regional distribution. The cyclotron bombards enriched ¹⁸O-water with protons (typically 16–18 MeV) to produce ¹⁸F via the ¹⁸O(p,n)¹⁸F reaction. The ¹⁸F is then incorporated into FDG or other precursors via automated synthesis modules in hot cell radiopharmacy suites. Quality control testing — including radiochemical purity, sterility, endotoxin testing, and radionuclidic purity — must be completed before patient injection, all within the constraint of the rapidly decaying radiotracer.

5. Types and Variants of PET Scanners

From Standalone to Hybrid Systems

Standalone PET scanners — PET-only systems — were the clinical standard through the 1990s. These systems relied on external radionuclide transmission sources (⁶⁸Ge rods or ¹³⁷Cs sources) for attenuation correction, requiring lengthy transmission scans that reduced patient throughput and introduced additional radiation exposure. The co-registration of PET images with separately acquired CT or MRI scans was performed by software algorithms that were susceptible to patient motion and positional differences between scans. While PET-only systems remain in use in some research and low-resource settings, they have been largely supplanted by hybrid platforms.

The introduction of PET/CT in 1998 by David Townsend and Ron Nutt, and its commercial launch by CTI/Siemens in 2001, transformed clinical PET. By mounting a multi-slice CT scanner on the same gantry as the PET detector ring, the system acquires co-registered CT and PET data in a single session. The CT provides rapid, high-quality attenuation maps and precise anatomical localization of PET findings, reducing scan time from 45+ minutes to 15–20 minutes and dramatically improving diagnostic confidence. PET/CT now accounts for the vast majority of clinical PET installations worldwide. Similarly, PET/MRI systems integrate PET detectors with an MRI scanner, providing superior soft-tissue contrast for neurological, pelvic, and pediatric applications at the cost of greater complexity and cost.

Emerging Platforms: Digital PET and Total-Body PET

Digital PET systems replace analog PMT-based detector chains with direct digital SiPM readout, achieving coincidence timing resolutions below 210 ps (Siemens Biograph Vision) compared to 500–600 ps for analog systems. This timing performance enables the full benefit of TOF reconstruction, substantially improving image quality particularly for large patients. The Philips Vereos was the first fully digital PET/CT system, introduced in 2016, and all major vendors now offer digital platforms.

Total-body PET represents the most dramatic recent architectural innovation. The United Imaging uEXPLORER, with a 194 cm axial FOV encompassing the entire human body simultaneously, achieves a sensitivity 15–40 times greater than conventional systems. This sensitivity advantage can be traded for reduced injected activity (enabling low-dose protocols), shorter scan times (sub-minute whole-body imaging), or improved image quality. The uEXPLORER enables dynamic whole-body kinetic modeling — simultaneously tracking tracer kinetics in every organ from a single bolus injection — opening new frontiers in pharmacokinetics, drug development, and systems biology research.

Type	Key Feature	Axial FOV	Primary Clinical Use	Example Systems
PET-Only	Standalone, no anatomical fusion	15–22 cm	Research, neurology	Siemens ECAT EXACT
PET/CT	CT attenuation correction + anatomical overlay	15–26 cm	Oncology staging, whole-body	GE Discovery MI, Siemens Biograph mCT
PET/MRI	Simultaneous MRI + PET, SiPM-based	25–30 cm	Neurology, pediatrics, pelvis	Siemens Biograph mMR, GE SIGNA PET/MR
Digital PET/CT	SiPM detectors, TOF <210 ps	26 cm	All clinical indications	Siemens Biograph Vision, Philips Vereos
Total-Body PET	Ultra-long axial FOV, 15–40× sensitivity	194 cm	Dynamic imaging, pharmacokinetics, low-dose	United Imaging uEXPLORER, PennPET Explorer

6. Benefits of PET Scanners

Functional and Metabolic Imaging Capability

PET’s defining advantage is its ability to image physiology and biochemistry, not merely anatomy. Disease processes — malignancy, neurodegeneration, inflammation, ischemia — manifest as biochemical changes long before structural alterations are visible on CT or MRI. FDG-PET can detect metabolically active tumors as small as 5–7 mm in favorable locations, identify epileptic foci in structurally normal brains, and distinguish viable from necrotic or scarred myocardium. This functional sensitivity changes clinical management in a substantial proportion of patients: studies consistently demonstrate that PET alters treatment intent (curative vs. palliative) in 20–30% of cancer patients.

The ability to image at the molecular level also underpins drug development. PET occupancy studies use radiolabeled drug candidates or receptor tracers to directly measure drug-target binding in vivo, providing quantitative pharmacodynamic data that guides dose selection in phase I/II trials. This application — pharmaceutical PET imaging — has become a major driver of demand for novel PET tracers and scanner performance improvements in research settings.

Quantitative Measurements: SUV and Kinetic Modeling

Unlike most imaging modalities, PET provides quantitative measurements of radiotracer concentration in absolute units (kBq/mL), enabling standardized comparison across patients, scanners, and time points. The standardized uptake value (SUV) — the ratio of tissue radiotracer concentration to injected activity normalized by body weight — is the most widely used semi-quantitative metric. SUVmax (maximum voxel SUV within a lesion) is used to characterize lesion FDG avidity, guide biopsy selection, and assess treatment response. PERCIST criteria define response by percentage change in SULpeak (SUV normalized to lean body mass) on sequential PET scans.

Full kinetic modeling — using dynamic PET acquisitions with arterial input function measurement — yields absolute physiological parameters such as metabolic rate of glucose (MRGlc), blood flow (mL/min/g), receptor binding potential, and distribution volume. These parameters provide deeper biological insight and are increasingly used in clinical research. Total-body PET has made simultaneous whole-body kinetic modeling practical for the first time, enabling systemic pharmacokinetic studies that were previously impossible.

Whole-Body Staging Efficiency and Theranostics

The whole-body coverage of a single PET/CT scan — typically from skull base to mid-thigh in 15–20 minutes — provides comprehensive staging information in one examination, replacing multiple organ-specific tests with superior diagnostic accuracy. For lymphoma staging, PET/CT has replaced gallium scintigraphy and CT staging, with superior sensitivity for nodal and extranodal disease. In lung cancer, PET/CT upstages approximately 20% of patients compared to CT alone, preventing futile surgery in patients with occult metastases.

PET is also the cornerstone of the emerging theranostics paradigm: using the same molecular target for both diagnosis and therapy by pairing a diagnostic PET radiotracer with a therapeutic radiopharmaceutical bearing the same targeting vector. PSMA-PET (⁶⁸Ga-PSMA-11 or ¹⁸F-DCFPyL) identifies PSMA-expressing prostate cancer metastases, and patients who are PSMA-PET positive can be treated with ¹⁷⁷Lu-PSMA-617, a beta-emitting therapeutic analog. The VISION trial demonstrated a 4-month survival benefit with ¹⁷⁷Lu-PSMA therapy in PSMA-PET selected patients, exemplifying PET-guided precision oncology.

7. Risks and Limitations

Radiation Dose Considerations

PET involves ionizing radiation from both the radiotracer and, in PET/CT, the CT component. A standard whole-body FDG-PET study delivers an effective dose of approximately 7 mSv from the FDG itself, while the diagnostic CT component may add 5–15 mSv depending on protocol, for a combined effective dose of 12–22 mSv. By comparison, natural background radiation in the US averages approximately 3 mSv/year. The radiation risk from a single PET/CT is considered low but not negligible, particularly for young patients and those requiring multiple scans for disease surveillance.

ALARA (as low as reasonably achievable) principles guide PET dosimetry. Weight-based dosing protocols minimize injected activity; low-dose CT protocols (using automated tube current modulation) reduce the CT contribution; and improved scanner sensitivity — particularly total-body PET — enables diagnostic image quality at dramatically reduced injected activities. PET is generally contraindicated in pregnancy except in life-threatening clinical circumstances, and breastfeeding should be interrupted for 12–24 hours after FDG administration depending on institutional protocol.

Spatial Resolution and Cost Constraints

PET spatial resolution is fundamentally limited by two physical factors: the positron range before annihilation (varies by isotope — 0.2 mm for ¹⁸F to 2.6 mm for ⁸²Rb) and the non-collinearity of the 511 keV photon pair (a ~0.5° deviation from 180° introduces ~2–3 mm blurring at 80 cm detector ring diameter). These physical limits, combined with detector crystal size and reconstruction algorithm smoothing, result in clinical PET spatial resolution of approximately 4–6 mm FWHM — substantially worse than CT (0.5 mm) or MRI (1 mm). This limits detection of small lesions and accurate quantification of small structures due to the partial volume effect.

The capital and operational costs of PET programs are significant. A PET/CT system costs $1.5–3.5 million, a PET/MRI $5–8 million, and a total-body PET system approximately $10+ million. On-site cyclotron installation adds $3–5 million in capital costs plus ongoing operations staff. Reimbursement varies by country and indication; in the US, Medicare covers FDG-PET for most oncologic indications but coverage for newer tracers (PSMA, amyloid, tau) is still evolving. These economic factors create access disparities, with PET imaging concentrated in large academic and cancer centers.

Artifacts and Technical Challenges

PET images are susceptible to several artifacts that can mimic or obscure pathology. Attenuation correction artifacts are the most clinically significant: metal implants (hip prostheses, pacemakers, dental fillings) cause CT beam hardening and overestimation of attenuation, producing focal PET overcorrection artifacts that can simulate FDG-avid lesions. Respiratory motion causes misregistration between the CT attenuation map and PET data, creating diaphragm dome artifacts and blurring of pulmonary and hepatic lesions; respiratory gating techniques mitigate this at the cost of reduced counting statistics. Patient movement during the 15–20 minute PET acquisition similarly degrades image quality.

Physiological variants and pitfalls abound in FDG-PET interpretation. Brown adipose tissue (BAT) activation — particularly in cold-stressed patients — produces intense symmetric FDG uptake in the neck, supraclavicular regions, and paravertebral fat that can obscure lymph node disease. Hyperglycemia reduces FDG tumor uptake and increases background blood pool activity, degrading lesion-to-background contrast; blood glucose should be below 150–200 mg/dL before injection. Inflammatory conditions (post-surgical sites, infection, autoimmune disease) are FDG-avid and may be misinterpreted as malignancy, requiring careful clinical correlation.

8. Recent Innovations and Future Directions

Digital PET and Silicon Photomultiplier Technology

The replacement of analog PMT chains with digital SiPM readout — commercialized in the Philips Vereos (2016) and Siemens Biograph Vision (2019) — has delivered the most significant performance improvement in PET in two decades. The Biograph Vision achieves a coincidence timing resolution of 210 ps, enabling TOF kernels of approximately 3 cm FWHM, compared to approximately 9 cm for analog systems. This dramatically constrains where along each LOR the annihilation event occurred, improving effective sensitivity and image signal-to-noise ratio equivalently to increasing scanner sensitivity by a factor of 3–5 for typical patient sizes.

SiPMs also enable depth-of-interaction (DOI) measurement — determining where along the crystal depth a photon was absorbed — which corrects the parallax error that degrades spatial resolution at the periphery of the FOV in conventional detectors. Individual crystal readout (one SiPM per crystal vs. 4 PMTs per block) improves crystal identification and light sharing characterization. The MR compatibility of SiPMs (immune to magnetic fields up to at least 7 T) has enabled truly simultaneous PET/MRI in the Siemens Biograph mMR and GE SIGNA PET/MR, where PET and MRI data are acquired concurrently rather than sequentially.

Total-Body PET: The EXPLORER Platform

The EXPLORER total-body PET scanner, developed by a consortium led by Simon Cherry and Ramsey Badawi at UC Davis with United Imaging Healthcare, was installed in 2018 and achieved clinical deployment as the uEXPLORER. With a 194 cm axial FOV, the system captures essentially the entire human body simultaneously, using approximately 560,000 LYSO crystal elements and achieving a sensitivity 15–40 times higher than conventional PET/CT scanners. This extraordinary sensitivity enables imaging at injected activities 10–40 times lower than standard doses while maintaining diagnostic image quality, or alternatively, sub-minute whole-body scans at standard doses.

The simultaneous whole-body coverage enables dynamic whole-body kinetic modeling from a single bolus injection — tracking the temporal evolution of tracer concentration in every organ simultaneously. This capability opens new opportunities in systems pharmacology, drug development, and understanding of systemic disease processes. The PennPET Explorer (University of Pennsylvania) offers a 64 cm axial FOV as a cost-intermediate option. Multiple institutions worldwide now operate or are installing extended-axial-FOV PET systems, and long-axial-FOV systems from Siemens (Biograph Trinax, 106 cm) and other vendors are entering the market.

AI-Powered Image Reconstruction and Processing

Artificial intelligence and deep learning are transforming PET image reconstruction and post-processing. Deep learning-based denoising networks, trained on paired low-dose and standard-dose PET images, can generate standard-quality images from low-count acquisitions that would otherwise be diagnostically unusable. GE’s TrueFidelity and Siemens’ Deep Resolve (adapted to PET) implement vendor-supported deep learning reconstruction that simultaneously denoises, sharpens, and preserves quantitative accuracy. Studies have demonstrated that AI reconstruction enables 50–75% dose reduction while maintaining diagnostic image quality and SUV accuracy.

Beyond reconstruction, AI applications in PET include automated lesion detection and segmentation, automated SUV measurement and reporting, AI-based attenuation correction (inferring CT-equivalent attenuation maps from PET emission data alone — eliminating CT dose entirely), and predictive modeling of treatment response from pre-therapy PET radiomics features. In multi-modal workflows involving ultrasound, CT, MRI, and PET, AI-driven image fusion and report generation platforms are streamlining clinical workflows in integrated imaging centers.

Novel Radiotracers and the Theranostics Revolution

The radiotracer portfolio available for PET imaging has expanded dramatically in the past decade. ⁶⁸Ga-PSMA-11 (FDA-approved 2020) and ¹⁸F-DCFPyL (piflufolastat F-18, FDA-approved 2021) target prostate-specific membrane antigen (PSMA) on prostate cancer cells with sensitivity of approximately 85–90% and specificity of 97% for biochemically recurrent prostate cancer — far superior to conventional imaging and bone scan. Amyloid PET tracers (¹⁸F-florbetapir, florbetaben, flutemetamol — all FDA-approved) and tau PET tracers (¹⁸F-flortaucipir) enable definitive in vivo characterization of Alzheimer’s pathology, transforming dementia diagnosis and enabling enrollment in amyloid-targeting clinical trials.

The theranostics paradigm pairs diagnostic PET tracers with therapeutic radiopharmaceuticals sharing the same targeting vector. ⁶⁸Ga-DOTATATE PET for neuroendocrine tumors directs therapy with ¹⁷⁷Lu-DOTATATE (LUTATHERA, FDA-approved 2018); PSMA-PET guides ¹⁷⁷Lu-PSMA-617 (PLUVICTO, FDA-approved 2022) therapy in metastatic prostate cancer. The VISION trial demonstrated a 4-month improvement in overall survival with ¹⁷⁷Lu-PSMA-617 versus standard care, with patient selection based entirely on PSMA-PET positivity. This regulatory precedent — using a companion PET diagnostic to select patients for targeted radionuclide therapy — will drive further theranostics pair development across multiple tumor types.

9. Key Takeaways for Biomedical Engineers

Engineering Challenges in PET System Design

PET scanner design presents multifaceted engineering challenges spanning nuclear physics, solid-state electronics, mechanical precision, and software. Scintillator crystal selection requires balancing light yield, decay time, density, energy resolution, and cost — with LYSO currently dominating but newer materials (e.g., lanthanum bromide, barium fluoride for fast timing) under investigation. Timing circuit design demands picosecond-level precision: achieving sub-200 ps coincidence timing resolution requires custom ASIC design with low-noise front-end electronics, precise clock distribution across thousands of channels, and careful management of signal propagation delays. Radiation shielding design must account for 511 keV high-energy photons requiring lead or tungsten shielding substantially thicker than for conventional X-ray equipment.

Thermal management is critical: SiPM dark count rates and gain are temperature-dependent, requiring active temperature control of detector modules to maintain timing and energy resolution stability. Mechanical precision in detector ring assembly affects spatial resolution uniformity — detector positioning tolerances of <0.5 mm are required. For PET/MRI, electromagnetic compatibility between the PET electronics and MR gradient switching and RF pulses presents significant engineering challenges, requiring extensive shielding, filtering, and careful materials selection to avoid susceptibility artifacts and RF interference.

Quality Assurance and Regulatory Standards

PET scanner performance is characterized according to NEMA NU 2 standards, which define measurement protocols for spatial resolution, sensitivity, scatter fraction, noise equivalent count rate (NECR), count rate performance, and image quality phantom measurements. NEMA NU 2-2018 is the current version; these measurements form the basis of acceptance testing upon installation and periodic performance monitoring. Daily quality control typically includes a normalization scan using a uniform cylindrical phantom or rotating ⁶⁸Ge rod sources, daily blank scans to monitor detector gain and timing stability, and CT calibration for PET/CT systems.

Regulatory frameworks governing PET scanners include FDA 510(k) clearance or PMA approval (Class II medical devices), FDA device classification requirements under 21 CFR Part 892, IEC 60601-1 (general safety) and IEC 60601-2-44 (particular requirements for CT, applicable to PET/CT), and ISO 13485:2016 quality management system requirements for device manufacturers. Radiopharmacy operations are regulated separately under USP <797> and <825> standards for sterile radiopharmaceutical preparation. Nuclear Regulatory Commission (NRC) or Agreement State licenses govern the use of radioactive materials in PET programs.

Career Pathways and Future Outlook

Biomedical engineers play essential roles across the PET ecosystem. In industry, opportunities exist in PET detector hardware development, ASIC and electronics design, reconstruction algorithm development, AI/machine learning for image processing, cyclotron and synthesis module engineering, and regulatory affairs for new tracer and scanner approvals. In clinical settings, nuclear medicine engineers support scanner installation, acceptance testing, quality assurance programs, and integration with hospital information systems (RIS/PACS/EMR). Medical physicists with PET expertise oversee radiation safety programs, dosimetry calculations, and research protocol development.

The future of PET is shaped by three converging forces: total-body PET enabling previously impossible whole-body kinetic studies; AI transforming every step from acquisition protocol optimization to clinical report generation; and an expanding theranostics pharmacopoeia creating new demand for high-performance PET as a treatment-selection and response-monitoring tool. As healthcare systems globally recognize the cost-effectiveness of PET-guided oncology management, the modality will continue its transition from specialized academic resource to routine clinical infrastructure — creating sustained demand for the engineers who design, optimize, and maintain these extraordinary instruments.

References

1. NEMA NU 2-2018: Performance Measurements of Positron Emission Tomographs (PET). National Electrical Manufacturers Association, 2018. nema.org
2. IEC 60601-2-44:2009+AMD1:2012+AMD2:2016: Medical electrical equipment — Part 2-44: Particular requirements for X-ray equipment for computed tomography. International Electrotechnical Commission. iec.ch
3. Ter-Pogossian MM, Phelps ME, Hoffman EJ, Mullani NA. (1975). A Positron-Emission Transaxial Tomograph for Nuclear Imaging (PETT). Radiology. 114(1):89–98. doi:10.1148/114.1.89
4. Cherry SR, Jones T, Karp JS, Qi J, Moses WW, Badawi RD. (2018). Total-Body PET: Maximizing Sensitivity to Create New Opportunities for Clinical Research and Patient Care. J Nucl Med. 59(1):3–12. doi:10.2967/jnumed.116.184036
5. Surti S. (2015). Update on Time-of-Flight PET Imaging. J Nucl Med. 56(1):98–105. doi:10.2967/jnumed.114.145029
6. Hofman MS, Violet J, Hicks RJ, et al. (2018). [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer. Lancet Oncol. 19(6):825–833. doi:10.1016/S1470-2045(18)30198-0
7. Siemens Healthineers. Biograph Vision PET/CT. siemens-healthineers.com
8. GE HealthCare. Discovery MI PET/CT System. gehealthcare.com
9. ISO 13485:2016. Medical devices — Quality management systems — Requirements for regulatory purposes. ISO. iso.org
10. Jadvar H, Colletti PM. (2014). Competitive advantage of PET/MRI. Eur J Radiol. 83(1):84–94. doi:10.1016/j.ejrad.2013.05.028